Bausch Health Companies | VRX - Cash And Equivalent


Bausch Health Companies reported $1.31B in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Amgen USD 12.04B 2.91B Mar/2026
ANI Pharmaceuticals USD 311.18M 25.59M Mar/2026
Aurora Cannabis CAD 56.36M 39.33M Dec/2025
Bausch Health Companies USD 1.31B 1000K Dec/2025
Biogen USD 3.38B 374.2M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Canopy Growth CAD 371.32M 73.26M Dec/2025
Corcept Therapeutics USD 108.74M 11.76M Mar/2026
Danaher USD 5.7B 1.09B Mar/2026
Drreddys Laboratories INR 18.66B 9.65B Dec/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Pacira USD 144.31M 14.24M Mar/2026
Perrigo USD 531.6M 99.5M Dec/2025
Phibro Animal Health USD 54.93M 557K Mar/2026
Prestige Brands USD 63.87M 1.5M Mar/2026
Supernus Pharmaceuticals USD 184.87M 56.42M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026
Zoetis USD 1.94B 369M Mar/2026